Drug intelligence / Profile preview

Minhai varicella vaccine

Development stage: Unknown
Lead developer: Beijing Minhai Biological
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

The Minhai varicella vaccine is a lyophilized live attenuated vaccine derived from the Oka strain of the varicella-zoster virus (VZV). Developed by Beijing Minhai Biotechnology, it is designed to prevent chickenpox (varicella) in children. The vaccine works by inducing active immunity, including the production of VZV-specific antibodies and cell-mediated immune responses. It has been evaluated in Phase III clinical trials in China, specifically targeting healthy children aged 1 to 12 years to assess its safety and immunogenicity compared to existing varicella vaccines.

Brand names: Weierke
Other names: Oka strain varicella attenuated live vaccineLyophilized Live Attenuated Varicella VaccineVaricella Vaccine (Live)

Beyond the preview

Go deeper on Minhai varicella vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Minhai varicella vaccine.

Explore the full profile